In the literature, tocilizumab (an IL-6 inhibitor approved by the European Medicines Agency for the treatment of rheumatoid arthritis in 2009 and by the US Food and Drug Administration [US FDA] for COVID-19 treatment in 2020) and remdesivir (an antiviral approved by the US FDA in 2020) are two of the medicines included in the guidelines and are associated with few serious Adverse Drug Events (ADEs) during treatment for COVID-19 (Fan et al., 2020; Tleyjeh et al., 2021; Angamo et al., 2022; Yu et al., 2022). Here, IL6 is linked to COVID-19.